Who Paid My Doc
Akynzeo
Drug
NDC 69639-102-01
General payments
$19,365
Research payments
$0
Through program year 2023, $19,365 in general payments and $0 in research payments were reported against Akynzeo.
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
5 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2023 | General | $619 | 33 |
| 2022 | General | $557 | 34 |
| 2021 | General | $830 | 56 |
| 2020 | General | $50 | 3 |
| 2019 | General | $17,308 | 1,135 |
Breakdown
The top 5 of 32 recipients; each share is of general payments naming this product in 2023.
The top 5 of 11 specialties; each share is of general payments naming this product to practitioners with a specialty in 2023. Each practitioner is counted under their primary specialty.
The top 5 of 13 states; each share is of general payments naming this product in 2023 where a state was reported.
Prescribed to Medicare patients
Part D · data year 2024Part D claims
4,352
Drug cost
$4,699,780
| Part D drug | Name match | Relative to the largest | Prescribers | Claims | Drug cost |
|---|---|---|---|---|---|
| Akynzeo Fosnetupitant/Palonosetron | Same name | 74 | 4,152 | $4,531,624 | |
| Akynzeo Netupitant/Palonosetron Hcl | Same name | 8 | 200 | $168,156 |
Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.
Largest prescribers
First 5 of 82 by claims · 2024Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.
| Prescriber | Specialty | State | Claims | Drug cost | Related payments |
|---|---|---|---|---|---|
| Li- Teh Wu | Medical Oncology | NY | 158 | $152,118 | None on record |
| Noshir Dacosta | Medical Oncology | NY | 132 | $131,870 | None on record |
| Triantafillos Fillos | Medical Oncology | NY | 128 | $134,191 | None on record |
| Abhirami Vivekanandarajah | Internal Medicine | NY | 127 | $135,112 | None on record |
| George Cyriac | Hematology-Oncology | NY | 119 | $122,249 | None on record |
"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.
See more in the dashboard: 25 with a free account, all 82 with PatronGiven in the clinic
Part B · billing code| Billing code | Providers | Services | Paid by Medicare |
|---|---|---|---|
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg J1454 | 448 | 25,883 | $13,944,018 |
Drugs given by a clinician are billed to Medicare Part B, not Part D. The product is tied to a billing code through the NDC on CMS's crosswalk, which was published for a later quarter than the payments, so a code that changed in between can be missed. Providers with fewer than 11 patients for the code are not published. Medicare's payment here is what it paid for the services, to the billing practice.
Records
1,261 generalEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.